This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /pro/cpd-dashboard page

This video is worth 0.05 CPD credits. CPD Dashboard

Go to /account/subscription-details page

This video is worth 0.05 CPD credits. Upgrade to Pro

Esmya (ulipristal acetate): suspension of the licence

Posted 3 Apr 2020

Dr Julie Oliver

Julie Oliver summarises information from the MHRA regarding the suspension of the licence for Esmya (ulipristal acetate) while a safety review is conducted.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.